Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Bioorg Med Chem Lett ; 88: 129280, 2023 05 15.
Artículo en Inglés | MEDLINE | ID: mdl-37054759

RESUMEN

Starting from the dialkylaniline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor lead 3 (IDO1 HeLa IC50 = 7.0 nM), an iterative process of synthesis and screening led to cyclized analog 21 (IDO1 HeLa IC50 = 3.6 nM) which maintained the high potency of 3 while addressing issues of lipophilicity, cytochrome P450 (CYP) inhibition, hERG (human potassium ion channel Kv11.1) inhibition, Pregnane X Receptor (PXR) transactivation, and oxidative metabolic stability. An x-ray crystal structure of a biaryl alkyl ether 11 bound to IDO1 was obtained. Consistent with our earlier results, compound 11 was shown to bind to the apo form of the enzyme.


Asunto(s)
Inhibidores Enzimáticos , Éteres , Humanos , Relación Estructura-Actividad , Inhibidores Enzimáticos/química , Células HeLa , Indolamina-Pirrol 2,3,-Dioxigenasa
2.
Bioorg Med Chem Lett ; 28(4): 732-736, 2018 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-29398543

RESUMEN

A novel series of o-phenylenediamine-based inhibitors of indoleamine 2,3-dioxygenase (IDO) has been identified. IDO is a heme-containing enzyme, overexpressed in the tumor microenvironment of many cancers, which can contribute to the suppression of the host immune system. Synthetic modifications to a previously described diarylether series resulted in an additional degree of molecular diversity which was exploited to afford compounds that demonstrated significant potency in the HeLa human cervical cancer IDO1 assay. .


Asunto(s)
Inhibidores Enzimáticos/farmacología , Indolamina-Pirrol 2,3,-Dioxigenasa/antagonistas & inhibidores , Fenilendiaminas/farmacología , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/metabolismo , Células HeLa , Humanos , Microsomas Hepáticos/metabolismo , Fenilendiaminas/síntesis química , Fenilendiaminas/química , Fenilendiaminas/metabolismo , Relación Estructura-Actividad
3.
Cell Chem Biol ; 28(10): 1528-1538.e4, 2021 10 21.
Artículo en Inglés | MEDLINE | ID: mdl-34081921

RESUMEN

Proteolysis-targeting chimeras (PROTACs) represent a new direction in small-molecule therapeutics whereby a heterobifunctional linker to a protein of interest (POI) induces its ubiquitination-based proteolysis by recruiting an E3 ligase. Here, we show that charge reduction, native mass spectrometry, and gas-phase activation methods combine for an in-depth analysis of a PROTAC-linked ternary complex. Electron capture dissociation (ECD) of the intact POI-PROTAC-VCB complex (a trimeric subunit of an E3 ubiquitin ligase) promotes POI dissociation. Collision-induced dissociation (CID) causes elimination of the nonperipheral PROTAC, producing an intact VCB-POI complex not seen in solution but consistent with PROTAC-induced protein-protein interactions. In addition, we used ion mobility spectrometry (IMS) and collisional activation to identify the source of this unexpected dissociation. Together, the evidence shows that this integrated approach can be used to screen for ternary complex formation and PROTAC-protein contacts and may report on PROTAC-induced protein-protein interactions, a characteristic correlated with PROTAC selectivity and efficacy.


Asunto(s)
Proteínas de Ciclo Celular/metabolismo , Gases/química , Espectrometría de Movilidad Iónica/métodos , Factores de Transcripción/metabolismo , Ubiquitina-Proteína Ligasas/metabolismo , Proteínas de Ciclo Celular/química , Mapas de Interacción de Proteínas , Proteolisis , Factores de Transcripción/química , Ubiquitina-Proteína Ligasas/química
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda